Advertisement

Clinical Predictive Criteria for Response to Endocrine Treatment and the Receptor Status

  • H. Maass
  • W. Jonat
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 71)

Abstract

Oestrogen receptors have a well-established value in prediction of the response to endocrine treatment in advanced breast cancer. Recent data have given evidence that the receptor status could also be of value for predicting the chemotherapeutic effect. This was first pointed out by Lippman et al. (1978). A similar trend had been observed in the prospective trial being conducted by King (1978) and our own data also give the same impression (Jonat and Maass, 1978) (Table 1).

Keywords

Breast Cancer Estrogen Receptor Metastatic Breast Cancer Endocrine Treatment Receptor Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cooperative Breast Cancer Group: Progress report: Results of studies of the Cooperative Breast Cancer Group 1961–1963. Cancer Chemother. Rep. 41, 1 (1964)Google Scholar
  2. Council on Drugs: Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four patients. Report to the Council. JAMA 172, 1271 (1960)CrossRefGoogle Scholar
  3. Jensen, E.: Presented at the First Innsbruck Winter Conference on Biochemistry in Clinical Medicine, Jan. 1978. Innsbruck, Austria (to be published)Google Scholar
  4. Jonat, W., Maass, H.: Some comments on the necessity of receptor determination in human breast cancer. Cancer Res. 38, 4305–4306 (1978)PubMedGoogle Scholar
  5. King, R.: Presented at the First Innsbruck Winter Conference on Biochemistry in Clinical Medicine. Jan. 1978 Innsbruck, Austria (to be published)Google Scholar
  6. Knight, III, W. A., Livingston, R. B., Gregory, E. J., McGuire, W. L.: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37, 4669–4671 (1977)PubMedGoogle Scholar
  7. Korsten, G. B., Engelsman, E., Persijn, J. P.: Clinical value of estrogen receptors in advanced breast cancer. In: Estrogen receptors in human breast cancer. McGuire, W. L., Carbone, P. P., Vollmer, E. P. (eds.), pp. 93–105. New York: Raven Press 1974Google Scholar
  8. Leung, S. B., Moseley, H. S., Davenport, C. E., Krippaehne, W. W., Fletcher, W. S.: Estrogen receptor in prediction of clinical responses to endocrine ablation. In: Estrogen receptors in human breast cancer. McGuire, W. L., Carbone, P. P., Vollmer, E. P. (eds.), pp. 107–129. New York: Raven Press 1974Google Scholar
  9. Lippman, M. E., Allegra, J. C., Thompson, E. B., Simon, R., Barlock, A., Green, R. N. L., Huff, K. K., Do, H. M. T., Aitken, S. C., Warren, R.: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298, 1223–1228 (1978)PubMedCrossRefGoogle Scholar
  10. Stoll, B. A.: Hypothesis: breast cancer regression under oestrogen therapy. Br. Med. J. 1973 III, 446CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • H. Maass
    • 1
  • W. Jonat
    • 1
  1. 1.Kliniken der Freien Hansestadt Bremen, FrauenklinikZentralkrankenhaus St. Jürgen-StraßeBremen 1Germany

Personalised recommendations